Multiple Sclerosis (MS) and the COVID-19 Gap: Report available now

A new report “The socioeconomic cost of, and impact of COVID-19 on, multiple sclerosis in Canada” estimates substantial costs of MS to Canada.. The report estimates that, in a typical (non-disrupted) year, MS costs Canada $3.4 billion in direct health expenditure, productivity loss and other costs.  The independent report, authored by Deloitte Access Economics, also found nearly $600 million in additional social, economic and health costs resulting from the COVID-19 pandemic  through a combination of delayed MS diagnosis, and delayed or foregone MS treatment.

ACED partner MS Canada is mobilizing their MS community to write to the federal and provincial health ministers to prioritize the needs of the MS community and close the COVID gap.